Preventing Muscle Loss During GLP-1 Receptor Agonist Therapy: The Role of Functional Mocktails and Reforming Ultra-Processed Foods

Abstract

Background: GLP-1 receptor agonist therapy is thus efficient for treating type 2 diabetes and obesity but is associated with unwanted muscle loss that may affect the health and function of patients themselves.

Objective: Thus, the study aimed at understanding how to prevent muscle loss associated with GLP-1 RA therapy, determine the role of the functional mocktails in muscle retention, and explore means of reformulating ultra-processed foods into healthful diets.

Methodology: Using cross-sectional mixed methods, body composition analysis, and physical performance experimenting with GLP-1 RA-patients were employed alongside functional mocktail nutritional analysis profiling for an ultra-processed food assessment.

Results: Decreased significantly lean muscle mass and muscle function were found in patients and associated harm of protein intake with muscle preservation. Nevertheless, functional mocktails with protein forth-and both anti-inflammatory agents were found to be promising in muscle health retention, while ultra-processed food reformulation focusing more on nutrient density and less on unhealthy additives was also helpful.

Conclusion: Averting muscle loss on GLP-1 RA therapy therefore necessitates combined pharmacological and nutritional approaches. Mocktails with functional ingredients and reconfiguring ultra-processed foods provide promising avenues for the preservation of muscle and overall health outcomes.